<DOC>
	<DOC>NCT01042119</DOC>
	<brief_summary>The neurotoxin Botox (botulinum neurotoxin type A) is shown to be effective in the treatment of therapy refractory overactive bladder syndrome. Our data suggests a longer during efficacy than known from the use in striated muscle. The aim of our study is to analyze short- and longterm efficacy after Botox treatment and to evaluate risk factors for non-responders and side effects such as urinary retention.</brief_summary>
	<brief_title>Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<criteria>intravesical treatment with Botox at our clinic</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>botulinum neurotoxin type A</keyword>
	<keyword>BoNT/A</keyword>
	<keyword>Botox</keyword>
	<keyword>overactive bladder syndrome</keyword>
</DOC>